Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Sanduzzi-Zamparelli

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
The Lancet. Gastroenterology & Hepatology|April 8, 2019
Systemic doxorubicin and hepatocellular carcinoma: the end of an era never risen upMarco Sanduzzi-Zamparelli, Alejandro Forner
The Lancet. Oncology|December 16, 2021
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 studyMaria Reig, Marco Sanduzzi-Zamparelli
Hepatology (Baltimore, Md.)|December 10, 2024
The "shell game" after objective response in patients with advanced HCC treated with immunotherapyMarco Sanduzzi-Zamparelli, Giuseppe Cabibbo
Liver International : Official Journal of the International Association for the Study of the Liver|March 14, 2025
Surveillance in HCC: Making the Most of What We Have TodayMarco Sanduzzi-Zamparelli, Giuseppe Cabibbo
Nature Reviews. Clinical Oncology|June 3, 2018
Locoregional versus systemic therapy - robust positive data remain elusiveMarco Sanduzzi-Zamparelli, Jordi Bruix
United European Gastroenterology Journal|January 24, 2024
Systemic therapies in hepatocellular carcinoma: A revolution?Marta Fortuny, Marco Sanduzzi-Zamparelli, Maria Reig
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 15, 2018
New Systemic Treatments in Advanced Hepatocellular CarcinomaMarco Sanduzzi-Zamparelli, Álvaro Díaz-Gonzalez, María Reig
Alimentary Pharmacology & Therapeutics|December 19, 2019
Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' replyMarco Sanduzzi-Zamparelli, Víctor Sapena, Jordi Bruix, et al.
Viruses|May 5, 2019
Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral AgentsMarco Sanduzzi-Zamparelli, Loreto Boix, Cassia Leal, et al.
United European Gastroenterology Journal|November 23, 2017
The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinomaMarco Sanduzzi Zamparelli, Alba Rocco, Debora Compare, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
The Lancet. Gastroenterology & Hepatology|April 8, 2019
Systemic doxorubicin and hepatocellular carcinoma: the end of an era never risen upMarco Sanduzzi-Zamparelli, Alejandro Forner
The Lancet. Oncology|December 16, 2021
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 studyMaria Reig, Marco Sanduzzi-Zamparelli
Hepatology (Baltimore, Md.)|December 10, 2024
The "shell game" after objective response in patients with advanced HCC treated with immunotherapyMarco Sanduzzi-Zamparelli, Giuseppe Cabibbo
Liver International : Official Journal of the International Association for the Study of the Liver|March 14, 2025
Surveillance in HCC: Making the Most of What We Have TodayMarco Sanduzzi-Zamparelli, Giuseppe Cabibbo
Nature Reviews. Clinical Oncology|June 3, 2018
Locoregional versus systemic therapy - robust positive data remain elusiveMarco Sanduzzi-Zamparelli, Jordi Bruix
United European Gastroenterology Journal|January 24, 2024
Systemic therapies in hepatocellular carcinoma: A revolution?Marta Fortuny, Marco Sanduzzi-Zamparelli, Maria Reig
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 15, 2018
New Systemic Treatments in Advanced Hepatocellular CarcinomaMarco Sanduzzi-Zamparelli, Álvaro Díaz-Gonzalez, María Reig
Alimentary Pharmacology & Therapeutics|December 19, 2019
Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' replyMarco Sanduzzi-Zamparelli, Víctor Sapena, Jordi Bruix, et al.
Viruses|May 5, 2019
Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral AgentsMarco Sanduzzi-Zamparelli, Loreto Boix, Cassia Leal, et al.
United European Gastroenterology Journal|November 23, 2017
The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinomaMarco Sanduzzi Zamparelli, Alba Rocco, Debora Compare, et al.
Pageof 6